Skip to content
Dr. Cannabis

Peppery, woody, spicy

Beta-caryophyllene

The one cannabis terpene with an established direct cannabinoid-receptor mechanism. It is a selective CB2 agonist — and CB2 activation is not intoxicating.

Preclinical onlySupported only by laboratory or animal studies, frequently at doses far above what a cannabis product delivers. No human clinical evidence.
Aroma
Peppery, woody, spicy
Also found in
Black pepper, Cloves, Cinnamon

A 2008 PNAS paper established beta-caryophyllene as a selective CB2 receptor agonist, and called it a "dietary cannabinoid" because it is present in black pepper and cloves and is approved as a food additive. CB2 receptors sit largely in peripheral and immune tissue, which makes anti-inflammatory activity mechanistically plausible without any psychoactive effect.

This is the strongest terpene story in cannabis — and it still has an important caveat. A 2020 study in Frontiers in Pharmacology found the CB2 binding weak and without functional consequence in their assay, and found no modification of THC signalling by any terpene tested.

Analgesic effects are documented in mouse inflammatory and neuropathic pain models. No human randomised trial establishes a clinical effect of beta-caryophyllene at the doses a cannabis product delivers.

What marketing claims

  • • Anti-inflammatory
  • • Pain relief
  • • Non-intoxicating cannabinoid activity

What the evidence supports

Best-established mechanism of any cannabis terpene, but still without human clinical trials at realistic doses. Two well-conducted studies disagree on functional significance.

Conditions where Beta-caryophyllene shows up in the suggested profile

Sources

  1. Gertsch J, Leonti M, Raduner S, et al. Beta-caryophyllene is a dietary cannabinoid. PNAS. 2008;105(26):9099-9104.(DOI 10.1073/pnas.0803601105)Accessed 2026-08-15.
  2. Finlay DB, Sircombe KJ, Nimick M, Jones C, Glass M. Terpenoids From Cannabis Do Not Mediate an Entourage Effect by Acting at Cannabinoid Receptors. Frontiers in Pharmacology. 2020;11:359.(DOI 10.3389/fphar.2020.00359)Accessed 2026-08-15.
  3. Smith CJ, Vergara D, Keegan B, Jikomes N. The phytochemical diversity of commercial Cannabis in the United States. PLOS ONE. 2022;17(5):e0267498.(DOI 10.1371/journal.pone.0267498)Accessed 2026-08-15.